Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Deininger

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Haematologica|February 2, 2023
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysisJerald P Radich, Matthew Wall, Susan Branford, et al.
Leukemia|May 16, 2024
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up resultsJorge E Cortes, Koji Sasaki, Dong-Wook Kim, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Chronic Myelogenous Leukemia, Version 1.2014Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
British Journal of Haematology|March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Chronic myelogenous leukemia, version 1.2015Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
The New England Journal of Medicine|March 2, 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood|April 12, 2012
Zebrafish screen identifies novel compound with selective toxicity against leukemiaSuzanne Ridges, Will L Heaton, Deepa Joshi, et al.
Haematologica|April 6, 2006
The effect of prior exposure to imatinib on transplant-related mortalityMichael Deininger, Michael Schleuning, Hilde Greinix, et al.
Leukemia|March 23, 2023
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy resultsMichael J Mauro, Timothy P Hughes, Dong-Wook Kim, et al.
Haematologica|May 4, 2019
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditionsPeter Valent, Attilio Orazi, Michael R Savona, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Haematologica|February 2, 2023
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysisJerald P Radich, Matthew Wall, Susan Branford, et al.
Leukemia|May 16, 2024
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up resultsJorge E Cortes, Koji Sasaki, Dong-Wook Kim, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Chronic Myelogenous Leukemia, Version 1.2014Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
British Journal of Haematology|March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Chronic myelogenous leukemia, version 1.2015Susan O'Brien, Jerald P Radich, Camille N Abboud, et al.
The New England Journal of Medicine|March 2, 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisSrdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Blood|April 12, 2012
Zebrafish screen identifies novel compound with selective toxicity against leukemiaSuzanne Ridges, Will L Heaton, Deepa Joshi, et al.
Haematologica|April 6, 2006
The effect of prior exposure to imatinib on transplant-related mortalityMichael Deininger, Michael Schleuning, Hilde Greinix, et al.
Leukemia|March 23, 2023
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy resultsMichael J Mauro, Timothy P Hughes, Dong-Wook Kim, et al.
Haematologica|May 4, 2019
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditionsPeter Valent, Attilio Orazi, Michael R Savona, et al.
Pageof 8